Short Interest in Roche Holding AG (OTCMKTS:RHHBY) Increases By 37.3%

Roche Holding AG (OTCMKTS:RHHBY) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 3,887,775 shares, a growth of 37.3% from the November 30th total of 2,832,462 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 4,645,231 shares, the short-interest ratio is currently 0.8 days. Based on an average trading volume of 4,645,231 shares, the short-interest ratio is currently 0.8 days. Approximately 0.1% of the company’s shares are sold short.

Roche Trading Up 0.1%

Shares of OTCMKTS RHHBY traded up $0.07 during midday trading on Tuesday, hitting $51.87. The company’s stock had a trading volume of 341,337 shares, compared to its average volume of 2,172,778. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.80. Roche has a 1-year low of $34.75 and a 1-year high of $53.00. The firm’s fifty day moving average price is $46.85 and its 200-day moving average price is $43.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RHHBY. Curio Wealth LLC acquired a new stake in Roche in the 3rd quarter valued at about $25,000. Oakworth Capital Inc. bought a new stake in shares of Roche in the 3rd quarter worth approximately $57,000. First Horizon Advisors Inc. lifted its stake in Roche by 81.2% during the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock valued at $75,000 after purchasing an additional 826 shares during the last quarter. Salomon & Ludwin LLC boosted its holdings in Roche by 256.6% during the third quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock worth $129,000 after buying an additional 2,053 shares in the last quarter. Finally, Douglass Winthrop Advisors LLC bought a new stake in Roche during the third quarter worth approximately $201,000.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Morgan Stanley restated an “underweight” rating on shares of Roche in a report on Tuesday, December 2nd. Zacks Research downgraded shares of Roche from a “hold” rating to a “strong sell” rating in a research note on Friday, December 5th. JPMorgan Chase & Co. raised shares of Roche from an “underweight” rating to a “neutral” rating in a research note on Monday, December 8th. Hsbc Global Res upgraded shares of Roche from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 2nd. Finally, Jefferies Financial Group downgraded Roche from a “hold” rating to a “moderate sell” rating in a research note on Monday, October 27th. Three equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.00.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.